{"filings":[{"id":91148,"accession_number":"0001082554-26-000021","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.","Tyvaso DPI grew 9% to $330.3M but Nebulized Tyvaso fell 22% to $127.2M; Orenitram up 12%.","Cost of sales surged 44% to $133.4M, with $26.8M inventory reserve loss on Tyvaso DPI supply agreement.","Board authorized $2B share repurchase; $1.5B accelerated buyback executed; $500M remaining.","Positive ADVANCE OUTCOMES and TETON-1 study results; plans to develop ralinepag DPI for PH/fibrosis."],"consensus_eps_estimate":null,"consensus_eps_actual":5.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":781500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101085,"accession_number":"0001104659-26-036445","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.","Nebulized Tyvaso significantly reduced risk of clinical worsening; benefits seen across all subgroups.","Integrated analyses of TETON-1 and TETON-2 show statistically significant treatment effects on primary and most secondary endpoints.","Plan to submit sNDA to FDA by summer 2026 for priority review to add IPF indication for Tyvaso.","Safety profile consistent with prior Tyvaso studies; no new safety signals observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101084,"accession_number":"0001104659-26-025331","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approves up to $2B stock repurchase program through March 9, 2027.","ASR agreements with Citibank total $1.5B: $750M uncollared and $750M collared.","Initial delivery of ~992,120 shares (uncollared, ~70%) and ~708,657 shares (collared, ~50%) on March 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101083,"accession_number":"0001104659-26-021869","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.","Statistically significant improvements in 6MWD, NT-proBNP, and 47% increased odds of clinical improvement at Week 28.","80% of patients on dual background therapy; safety consistent with prostacyclin class; no new signals.","Company plans to submit NDA to FDA by second half of 2026.","Full results to be presented at upcoming international conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101082,"accession_number":"0001082554-26-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.","Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).","Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).","Orenitram sales $496.9M (+14% YoY).","Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":27.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":3182700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101081,"accession_number":"0001104659-26-005810","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.","Bylaw amendments: create cure process for shareholder nomination deficiencies; lower shareholder vote to amend bylaws from 80% to majority.","Tracey is President/CEO of Feinstein Institutes, co-founder of SetPoint Medical; brings expertise in inflammation and bioelectronic medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117430,"accession_number":"0001082554-25-000036","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.","Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).","Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.","TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.","Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":20.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2392500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133839,"accession_number":"0001104659-25-085976","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).","Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.","Safety profile consistent with prior Tyvaso studies; no new safety signals observed.","Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133838,"accession_number":"0001104659-25-073163","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"United Therapeutics enters $1B accelerated share repurchase agreements with Citibank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.","Uncollared ASR: initial delivery ~1.27M shares (75% of expected); final settlement expected Q4 2025 based on VWAP less discount.","Collared ASR: initial delivery ~850K shares (50% of expected); additional delivery after hedging; final settlement expected Q1 2026 with collar.","At July 30, 2025, company had ~45.2M shares outstanding; CEO cites confidence in intrinsic value and cash flow generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133837,"accession_number":"0001628280-25-036543","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.","Board authorized up to $1 billion in share repurchases through March 31, 2026.","Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.","Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.","Net income of $309.5 million, or $6.86 per basic share, up 11%."],"consensus_eps_estimate":null,"consensus_eps_actual":13.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1593000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150584,"accession_number":"0001104659-25-063287","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve amended 2015 Stock Incentive Plan; increase share reserve by 950k shares and extend plan to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2015 Stock Incentive Plan, increasing share reserve by 950,000 shares to 14,770,000 total.","Plan expiration extended to April 24, 2035; Lead Independent Director retainer increased by $5,000 per year.","All 12 director nominees elected; say-on-pay passed with ~95% of votes cast.","The stock plan amendment passed with ~92% of votes cast; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150583,"accession_number":"0001082554-25-000024","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).","Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.","R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.","Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney."],"consensus_eps_estimate":null,"consensus_eps_actual":6.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":794400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150582,"accession_number":"0001104659-25-039710","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"United Therapeutics enters $2.5B revolving credit facility, repays $200M of existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $2.5B unsecured revolving credit facility, with option to increase by up to $750M.","Borrowed $200M at closing to repay outstanding indebtedness under 2022 credit agreement.","Five-year maturity, with two potential one-year extensions at lenders' option.","Financial covenants: consolidated total leverage ≤3.50x and interest coverage ≥3.00x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169543,"accession_number":"0001082554-25-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.","Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).","Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).","Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.","Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects."],"consensus_eps_estimate":null,"consensus_eps_actual":24.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2877400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169542,"accession_number":"0001104659-25-002892","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Therapeutics presents at J.P. Morgan Healthcare Conference; no specific financials disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation slides filed as Exhibit 99.1 but full content not provided in the filing text.","Company provided business overview and update during Q&A session on January 13, 2025.","No material new financial or operational data available from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186589,"accession_number":"0001082554-24-000049","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).","Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.","Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.","Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.","Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver."],"consensus_eps_estimate":null,"consensus_eps_actual":18.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2141500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203162,"accession_number":"0001082554-24-000037","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.","Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.","Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).","R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.","Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":12.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1392600000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219479,"accession_number":"0001104659-24-075375","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"United Therapeutics shareholders elect Jan Malcolm to board, approve stock plan amendment adding 1.32M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan Malcolm, former Minnesota Health Commissioner, elected to board; replaces Prof. Katherine Klein who did not stand for re-election.","Shareholders approved amendment to 2015 Stock Incentive Plan: adds 1,320,000 shares, extends expiration to April 25, 2034.","All 11 director nominees elected; advisory resolution on executive compensation passed with 94.8% of votes cast.","Ratification of Ernst & Young as independent auditor for 2024 approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219478,"accession_number":"0001082554-24-000027","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.","Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.","Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.","Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).","Revenue growth driven by increased patient utilization and Part D redesign tailwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":6.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":677700000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}